CD274 and non-small cell lung carcinoma: Consolidation therapy with durvalumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, has become the standard treatment after chemoradiotherapy (CRT) in patients with unresectable locally advanced non-small cell lung cancer (NSCLC) [1].